sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial

Coronary Artery Disease Clinical Trial

— SPIDER-PCI  

Official title:

sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00533039
• Other study ID #: SPIDER001
• Secondary ID: A Sub-study of S
• Status: Completed
• Phase: Phase 2
• First received: September 19, 2007
• Last updated: October 8, 2009
• Start date: October 2007
• Est. completion date: June 2009

Study information

• Verified date: June 2008
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

As evidence accumulates that atherogenesis or Coronary Artery Disease (CAD) may not be simply a disorder of lipid metabolism, but an inflammatory disease, the focus of treatment has shifted. A-002 or Varespladib is an anti-inflammatory drug for treatment of chronic and acute diseases. It acts by inhibiting secretory phospholipase A2 (sPLA2 ) - one of a family of enzymes leading to inflammation - which may be important in: 1) the development of atherosclerosis and 2) the increase in occurence of cardiovascular events after angioplasty. Previous studies have demonstrated that sPLA2: 1) facilitates the pro-atherogenic effects of low-density (LDL or bad cholesterol) and 2) increased levels post-angioplasty correlate with an increased risk of events at followup contact. Therefore this study proposes to investigate the ability of A-002 to prevent or reduce myocardial damage after angioplasty by inhibiting the cascade of inflammatory mediators.

Substudy - Subjects who agree will also have a vascular ultrasound 24h post-PCI to assess endothelial function.

Description:

Tissue injury after angioplasty is likely due to micro-emboli from mechanical trauma to a thrombotic lesion during angioplasty. In response to the ischemia sPLA2, possibly localized within atherosclerotic vascular tissue as well as from macrophages and monocytes, is released. Following ischemia-induced release, sPLA2 can bind to ischemically challenged cardiomyocytes and adversely affect their survival either directly through toxic effects on cardiomyocytes or indirectly by facilitating inflammation. It may be possible through sPLA2 inhibition to salvage non-lethally jeopardized cells following an ischemic episode thereby reducing the infarcted area and amount of tissue damage. Previous studies in patients with unstable angina support this hypothesis, and conclude that sPLA2 levels can be used to predict clinical outcomes. We hypothesize that sPLA2 inhibition with A-002 will reduce myocardial injury post-angioplasty.

Substudy - Peripheral vascular ultrasound should be done prior to receiving study drug and 24h post-PCI. Coronary endothelial function will be assessed at the time of PCI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 164
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men or women = 18 years of age undergoing elective PCI, with or without stenting

Exclusion Criteria:

• ST elevation MI or any troponin elevation (non-STEMI) within preceding 10days

• Elevation of CK-MB or troponin I at baseline

• Recent (4 weeks) coronary bypass surgery

• NYHA class III-IV heart failure

• Left ventricular ejection fraction < 0.30

• Severe valvular heart disease

• Chronic inflammatory disease (e.g., lupus, rheumatoid arthritis, inflammatory bowel disease), or patients receiving steroid drugs

• Presence of severe liver disease with cirrhosis

• Recent active hepatitis

• Active chronic hepatitis

• ALT or AST > 3 × upper limit of normal (ULN)

• Biliary obstruction with hyperbilirubinemia (total bilirubin > 2 × ULN)

• Moderate or severe renal impairment (creatinine > 1.5 × ULN)

• Nephrotic syndrome or subjects undergoing dialysis

• Uncontrolled diabetes (HbA1c > 11% 1 month prior to screening)

• Initiation of statin therapy within 30 days

• Inability to provide consent.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Drug:
• Varespladib (A-002)
250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
• placebo
250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.

Locations

Country	Name	City	State
Canada	Toronto General Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Anthera Pharmaceuticals

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be incidence of myocardial injury as evidenced by elevation of CK-MB or troponin I above the upper limit of normal.		8 hours and 18-24 hours post-angioplasty	Yes
Secondary	A secondary endpoint will be occurrence of elevation of CK-MB or troponin I above the upper limit of normal.		8 and 18-24 hours post-angioplasty	Yes
Secondary	A secondary endpoint will be occurrence of any major adverse cardiac events (MACE).		30 days post-angioplasty	Yes
Secondary	A secondary outcome will be serum sPLA2 activity.		5-7 days post-angioplasty	Yes